Trulicity

Analysts at Credit Suisse downgraded Eli Lilly and Co (NYSE: LLY) in October and just three months later, the firm believes another downgrade is warranted. The Analyst Credit Suisse's Vamil Divan downgraded Eli Lilly's stock from Neutral to Underperform with a price target lowered...

The case for buying shares of Eli Lilly and Co (NYSE: LLY) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes franchise, according to Goldman Sachs.  The Analyst Goldman Sachs' Jami Rubin...

Argus analyst Katelyn Bayone believes shares of Eli Lilly and Co (NYSE: LLY) are fairly valued at around $81, which prompted her to downgrade the stock from Buy to Hold. According to Bayone, shares are trading near their 52-week high and also at a superior valuation versus its peers. In fact, the...

A day after Eli Lilly and Co (NYSE: LLY) reported earnings and sales misses for the third quarter, Goldman Sachs reduced its revenue and EPS estimate by 1–3 percent for 2016–2025 based on the conservative expectations of Jardiance, Humalog and Portrazza. However, the firm thinks that...